Progression of Renal Interstitial Fibrosis / Tubular Atrophy (IF/TA) According to Epithelial-mesenchymal Transition (EMT) and Immunosuppressive Regimen (Everolimus Based Versus CNI Based) in de Novo Renal Transplant Recipients

NCT01079143 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

194

Enrollment

INDUSTRY

Sponsor class

Conditions

Renal Interstitial Fibrosis

Interventions

DRUG: Certican®
DRUG: Neoral
DRUG: Myfortic
DRUG: Simulect®
DRUG: Corticosteroids

Sponsor

Novartis Pharmaceuticals